Biovance Capital Fund I invests in start-ups that are active in the Life Science and Biotech sectors. The Funds’s management team aligns their investment decisions according to a defined set of ESG criteria.
Biovance Capital Fund I and its management team evaluate each investment’s contribution to the SDGs and integrate them into investment decisions. Biovance Capital Fund I will invest in pursuing the maintenance of robust governance, compliance with regulatory obligations, and commitment to integrating environmental and social responsibilities into their activities. Biovance Capital Fund I invests in companies whose business development directly promotes the following SDGs:
The evaluation of sustainability indicators to verify the fulfillment of the Fund’s social and environmental objectives is carried out through two key approaches:
I. Contribution to the Sustainable Development Goals (SDGs)
Biovance Capital Fund I will actively integrate sustainability into its investment strategy by setting measurable SDG-related post-investment goals and targets. These targets shall align with the investee companies’ business plans and activities. In addition, Biovance Capital Fund I will follow the recently released frameworks for the ESG Convergence for European Lifes Sciences VC Project, an initiative by European Life Sciences VC firms, and Invest Europe ESG Reporting, aiming to harmonize and simplify ESG data collection.
SDG 3 – Goal
- Ensure healthy lives and promote well-being for all ages
- Contribution – Direct
- Key Metrics – Number of patients gaining early access to clinical trials conducted by the invested companies.
SDG 8
- Goal – Promote sustained, inclusive, and sustainable economic growth, full and productive employment and decent work for all
- Contribution – Indirect
- Key Metrics – Number of new differentiated jobs in Life Sciences in companies that prioritize ethical labour practices, workforce development and equitable opportunities, the implementation of a workplace accident prevention policy, a supplier code of conduct, and anti-corruption and anti-bribery policies.
SDG 9
- Goal – Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation
- Contribution – Indirect
- Key Metrics – Number of patents submitted and granted for Biotech-based therapeutics promoted by the invested companies for people in need.
The various targets under each objective are defined in the Pre-Contractual Disclosures.
